当前位置： SCI文献检索 > DIABETES & METABOLISM期刊下所有文献 > Insulin therapy for type 2 diabetes: premixed or basal-prandial?

Insulin therapy for type 2 diabetes: premixed or basal-prandial?

Abstract：

:It is logical to begin type 2 insulin therapy with an injection of an intermediate-acting or a long-acting insulin at bedtime, but one should treat to target, i.e. aim at fasting glycaemias lower than 1.20 g/l to obtain an HbA(1c) close to 7%. Nevertheless, basal insulin therapy does not prevent progression to insulin-secretory deficiency. If necessary, recourse should be made to multiple-injection protocols, taking into account postprandial hyperglycaemia. For every level of HbA(1c), the suppression of postprandial hyperglycaemia, 1 point of HbA(1c) can be gained in theory, whereas reducing the fasting glycaemia to values of less than 1.10 g/l reduces HbA(1c) to close to 7%, whatever the initial level of HbA(1c). However, when a diabetic is clearly not controlled, the preprandial acting use of rapid analogues allows the fasting glycaemia to be improved significantly. Inversely, an early treatment with basal insulin, by correcting glucotoxicity, can also decrease postprandial hyperglycaemia. Many industry-sponsored studies comparing insulin therapy regimens show annoying biased interpretations of results. It does not seem pertinent to compare a single injection with two or even three injections, nor to compare an efficient titration with an inefficient titration or to eliminate oral drugs, in particular sulphonylureas combined with a basal insulin. If premix insulins can give satisfactory results in patients who maintain a sufficient residual insulin-secretion, we think it would be preferable to adopt the basal-prandial regimen and a step-by-step escalating therapy. The first stage consists in combining oral therapy with an injection of NPH insulin or a long-acting analogue at bedtime, aiming at a fasting glycaemia of less than 1.20 g/l. In the next stages, a single injection of rapid-acting insulin analogue is added each time. The main advantage of this regimen is to fix a target adapted to each injection and, as a result, to facilitate forced titration of the doses.

journal_name

Diabetes Metab

journal_title

Diabetes & metabolism

authors

Halbron M,Jacqueminet S,Sachon C,Bosquet F,Hartemann-Heurtier A,Grimaldi A

doi

10.1016/j.diabet.2007.01.005

subject

Has Abstract

pub_date

2007-09-01 00:00:00

pages

316-20

issue

eissn

1262-3636

issn

1878-1780

pii

S1262-3636(07)00062-6

journal_volume

pub_type

杂志文章

在线工具

Insulin therapy for type 2 diabetes: premixed or basal-prandial?